Teprotumumab

(Tepezza®)

Teprotumumab

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 500 mg/vial)
Drug ClassInsulin-like growth factor-1 receptor inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of thyroid eye disease.

Product Monograph / Prescribing Information

Document TitleYearSource
Tepezza (teprotumumab-trbw) Prescribing Information.2021Horizon Therapeutics USA Inc., Lake Forest, IL

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines